Posts tagged ‘European Association of Urology’
March 3rd, 2012
At the recent European Association of Urology (EAU) Annual Congress in Paris, one of the rumours was that the price of abiraterone (Zytiga) has been discounted 40% to the UK National Health Service (NHS) in order to obtain reimbursement approval from the National Institute for Health & Clinical Excellence (NICE).
As Sally notes in her video report from EAU 2012, if true, this has important commercial implications in the advanced prostate cancer market and potential new entrants such as MDV3100.
When looking at the prostate cancer competitive landscape and a market entry strategy, one of the issues to consider is reimbursement.
Regulatory approval to market a drug in Europe does not automatically mean it will be reimbursed or paid for by healthcare providers. Abiraterone is a good example of this.
Another driver of price and reimbursement will be the cumulative cost of treatment for advanced prostate cancer. This is set to increase dramatically as new products such as MDV3100 and Alpharadin come to market, and their use moves from post-chemotherapy to the pre-chemotherapy setting.
You can gain more insights on some of the future challenges by watching Sally’s excellent conference coverage video from EAU 2012:
There is also more information from EAU 2012 on Biotech Strategy Blog e.g. on Bayer’s Expanded Access Program for Alpharadin and an update on Millennium’s orteronel (TAK-700), a competitor to abiraterone.
Sally’s next conference video will be from the forthcoming American Assocation for Cancer Research (AACR) 2012 annual meeting that takes in place Chicago from March 31 – April 4. We hope to see you there.
March 23rd, 2011
In a post that has provoked several comments, Pieter Droppert in a “letter from Vienna” discusses his observations about the sponsored sessions at the recent European Association of Urology Congress in Vienna.
In a meeting that featured a lot of innovative features such as webcasts of key presentations, the sponsored education sessions appeared too promotional.
Pieter’s blog post has prompted a debate as to whether these sessions were promotional or continuing medical education (CME), part of the Congress or not?
In the process it has raised the question of why European CME does not follow the same standards of independence and fair balance as US CME? Why do European medical congresses accept these type of quasi-promotional educational sessions?
As pharma marketing strategy consultants, we are all for promotional activities, but believe there needs to be a clear division between promotion and CME.
If you wish to enter the debate, and there’s nothing like a good bit of controversy to drive blog traffic, you can do so on Biotech Strategy Blog.
March 18th, 2011
Sally Church on Pharma Strategy Blog will be providing live coverage of the annual European Association of Urology (EAU) Congress that starts in Vienna this weekend.
If you can’t join Sally at the meeting for a slice of schwarzwälder kirschtorte, then you can experience the meeting virtually as Sally aggregates all the live tweets, and contributes her own.
There are a lot of new products in the prostate cancer market. With new treatment options such as Dendreon’s sipuleucel-T, sanofi-aventis’ cabizatexel and JNJ’s abiraterone expected in the not too distant future, the meeting is bound to be interesting. We can also expect the latest news about new product development in bladder and renal cancer.
The Cover it Live widget on Sally’s blog will be aggregating all the tweets that use the conference hashtag #EAU11, so if you are unable to be in Vienna, you can follow what’s happening by clicking here.
March 8th, 2011
Icarus Consultants will be at the forthcoming European Urology Association annual meeting in Vienna, Austria from March 18-22, 2011.
If you are going to be in Vienna and would be interested in meeting up for Kaffee Und Kuchen, please contact us.
Incidentally, our favorite is a slice of Schwarzwälder Kirschtorte (Black Forest gateau).